Related Experiment Video
Updated: May 30, 2026

Enrichment of Bruch's Membrane from Human Donor Eyes
Published on: November 15, 2015
Variation in complement component C1 inhibitor in age-related macular degeneration
J Gibson1, S Hakobyan, A J Cree
1Genetic Epidemiology & Bioinformatics Group, Human Genetics Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Insights
Plasma C1 inhibitor levels are significantly different in age-related macular degeneration (AMD) patients compared to controls. Genetic variations near the SERPING1 gene influence C1 inhibitor levels, suggesting a role in AMD pathogenesis.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss.
- The complement system, particularly C1 inhibitor (C1inh), plays a role in inflammatory processes.
- Understanding factors influencing C1inh levels may provide insights into AMD.
Purpose of the Study:
- To investigate plasma C1 inhibitor (C1inh) levels in patients with age-related macular degeneration (AMD) and healthy controls.
- To explore associations between C1inh levels and AMD, demographic factors, and genetic variations in the SERPING1 gene.
Main Methods:
- Plasma C1inh protein levels were measured using rate nephelometry in 391 AMD cases and 370 controls.
- Multivariate analysis was employed to assess relationships between C1inh levels and age, gender, smoking status, AMD status, and SERPING1 gene variants.
- Single nucleotide polymorphism (SNP) rs2649663 near the SERPING1 gene was analyzed for its association with C1inh levels.
Main Results:
- Significantly higher C1inh levels were observed in AMD cases compared to controls (p=2.340E-6).
- C1inh levels were also significantly associated with smoking status (p=1.022E-4) and gender (p=1.661E-7).
- AMD status remained a significant factor after adjusting for gender and smoking. A SNP (rs2649663) 5' of SERPING1 was associated with C1inh levels but not AMD.
Conclusions:
- Plasma C1inh levels are significantly elevated in individuals with AMD.
- Genetic variations in the promoter region of the SERPING1 gene may influence C1inh expression and potentially contribute to AMD development.
- Further research is warranted to elucidate the precise role of C1inh in AMD pathogenesis.
Abstract:
This study assessed variation in plasma levels of the complement regulatorC1 inhibitor (C1inh) in patients with age related macular degeneration (AMD) and controls. Plasma from391 AMD cases and 370 controls was assayed by rate nephelometry to determine C1inh protein levels. Protein levels were analysed for relationships with age, gender, smoking, AMD disease status and genetic variation in the SERPING1 gene, which encodes C1inh, using a multivariate analysis. t-Tests show a significant difference in C1inh levels in AMD cases compared with controls (p=2.340E-6), smokers compared to non-smokers (p=1.022E-4) and females compared to males (p=1.661E-7). Multivariate analysis shows that after accounting for gender and smoking AMD status remained significant. Age was included in the model but was not significant. Including genetic variation in the model shows that one significant SNP (rs2649663) 5' of the SERPING1 gene is associated with C1inh levels though this SNP is not associated with AMD. This suggests that genetic variation in the promoter region of the SERPING1 gene may influence expression of the gene.
More Related Videos
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacodynamics in Geriatric Patients: Effects of Age
Complement System
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

